Expertise in
23
conditions

Dr. Janos L. Tanyi

Gynecologic Oncology | Oncology
University Of Penn-Medical Group
800 Spruce St, 
Philadelphia, PA 
Offers Telehealth
Expertise in
23
conditions
University Of Penn-Medical Group
800 Spruce St, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Janos Tanyi is a Gynecologic Oncologist and an Oncologist in Philadelphia, Pennsylvania. Dr. Tanyi is highly rated in 23 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Hysterectomy, and Bladder Reconstruction.

His clinical research consists of co-authoring 85 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Licenses
Obstetrics & Gynecology in PA
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Penn Presbyterian Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UNIVERSITY OF PENN-MEDICAL GROUP
800 Spruce St, Philadelphia, PA 19107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Procedure, Device, Drug
Study Phase: Phase 3
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Randomized Pilot Trial to Test the Addition of Montanide and Polyiclc to Autologous Oxidized Tumor Cell Lysate Vaccine in Combination With Gmcsf in Primary Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized Pilot Trial to Test the Addition of Montanide and Polyiclc to Autologous Oxidized Tumor Cell Lysate Vaccine in Combination With Gmcsf in Primary Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Terminated
Publish Date: April 24, 2020
Intervention Type: Other, Biological
Study Phase: Phase 1
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: April 04, 2019
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
A Pilot Clinical Trial of Dendritic Cell Vaccine Loaded With Autologous Tumor for Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
A Pilot Clinical Trial of Dendritic Cell Vaccine Loaded With Autologous Tumor for Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: June 11, 2018
Intervention Type: Biological
Study Phase: Early Phase 1
View 5 Less Clinical Trials

85 Total Publications

The Sensitivity and Specificity of Total Prostate Specific Antigen in the Diagnosis of Prostate Cancer in a Resource-Limited African Setting: A 5-Year Review in a Kenyan Hospital.
The Sensitivity and Specificity of Total Prostate Specific Antigen in the Diagnosis of Prostate Cancer in a Resource-Limited African Setting: A 5-Year Review in a Kenyan Hospital.
Journal: Clinical genitourinary cancer
Published: March 17, 2025
Similar Doctors
Expertise in
27
conditions
Dr. Emily M. Ko
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Expertise in
27
conditions
Dr. Emily M. Ko
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

University Of Penn-Medical Group

3400 Spruce St, 
Philadelphia, PA 
 (2.0 mi)
Languages Spoken:
English
See accepted insurances

Emily Ko is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Philadelphia, Pennsylvania. Dr. Ko is highly rated in 27 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Endometrial Stromal Sarcoma, Hysterectomy, and Lymphadenectomy.

Expertise in
24
conditions
Dr. Mark S. Shahin
Gynecologic Oncology | Oncology | Hospital Medicine
Expertise in
24
conditions
Dr. Mark S. Shahin
Gynecologic Oncology | Oncology | Hospital Medicine

Alliance Cancer Specialists

599 W State St, 
Doylestown, PA 
 (24.9 mi)
215-345-8444
Languages Spoken:
English
See accepted insurances

Mark Shahin is a Gynecologic Oncologist and an Oncologist in Doylestown, Pennsylvania. Dr. Shahin is highly rated in 24 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Lymphadenectomy.

Expertise in
21
conditions
Dr. Christina S. Chu
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Expertise in
21
conditions
Dr. Christina S. Chu
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

Cooper Gyn Oncology Association PC

2 Cooper Plz, 
Camden, NJ 
 (2.2 mi)
856-735-6209
Languages Spoken:
English
See accepted insurances

Christina Chu is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Camden, New Jersey. Dr. Chu is highly rated in 21 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tanyi's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 11 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile